Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the 'Company' or 'Nexalin') the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology.
Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, each of whom brings specialized expertise that aligns with Nexalin's Alzheimer's-focused initiatives. The restructured SAB will play a pivotal role in guiding the Company's scientific direction, clinical strategy, and biomarker-driven trial design for neurodegenerative and neuropsychiatric disorders.
'This enhanced advisory board reflects our sharpened focus on Alzheimer's disease, and the high-caliber expertise of Drs. Huang, Owens, and Scheer aligns with our expanding research agenda,' said Mark White, CEO of Nexalin Technology. 'Their combined contributions will be invaluable as we advance Nexalin's technology through clinical trials designed to address one of the greatest public health challenges of our time.'
Nexalin's Gen-2 SYNC and Gen-3 Halo™ headset delivers DIFS™, a proprietary waveform capable of penetrating deep brain structures implicated in cognitive decline and mental illness. Recent published articles and encouraging preclinical and early-stage human data suggest that DIFS™ may promote neuroplasticity and functional recovery in regions associated with memory and executive function. These findings have prompted the Company to intensify its focus on Alzheimer's disease, with the SAB's restructuring aimed at providing the scientific and clinical oversight required for this complex area of medicine.
Scientific Advisory Board Members
Dr. Mingxiong Huang is a globally recognized expert in magnetoencephalography (MEG) and neuroimaging, with over 25 years of experience developing and applying advanced imaging techniques to neurological and psychiatric disorders. He is Professor of Radiology at the University of California, San Diego (UCSD), Adjunct Professor in the Department of Electrical and Computer Engineering, Co-Director of the UCSD MEG Center, and a career research health scientist at the VA San Diego Healthcare System.
Dr. Huang earned his Ph.D. in biomedical physics from Northeastern University and completed postdoctoral training in MEG at Los Alamos National Laboratory. He previously held faculty positions at the University of New Mexico before joining UCSD. His work has been instrumental in advancing MEG source imaging, integrating MEG with structural and functional modalities such as diffusion tensor imaging, and applying these methods to conditions including TBI, PTSD, stroke, epilepsy, and schizophrenia. He has authored over 90 peer-reviewed publications and received the Distinguished Investigator Award from the Academy of Radiology Research. Dr. Huang's deep expertise in brain imaging biomarkers directly supports Nexalin's mission to develop data-driven, non-invasive therapies for Alzheimer's and other neurodegenerative disorders.
Dr. Abe Scheer served on the Company's prior SAB and brings more than four decades of experience in adult and pediatric neurology, psychiatry, brain injury medicine, and electrophysiology. Board certified by the American Board of Psychiatry and Neurology in both adult and pediatric neurology, as well as in brain injury medicine, Dr. Scheer has trained and held faculty positions at premier institutions including Columbia University, Cornell Medical College, Georgetown University, and the University of Pittsburgh. Dr. Scheer held the position of Director of Neurology and Stroke Services at Beebe Healthcare in Delaware for over 10 years. He is currently a neurohospitalist and neurointensivist at Bay Health in Delaware and maintains an attending role at MeadowWood Hospital in Delaware.
Dr. Scheer has lectured extensively across the U.S. on neuromodulation therapies and was instrumental in launching the first vagal nerve stimulation and baclofen pump clinics in Lincoln, Nebraska. He has served in advisory capacities for leading device developers including Medtronic, Cyberonics, and Milestone Scientific. A passionate educator, he continues to teach medical students and residents while contributing to clinical advancements in both neurology and psychiatry. His expertise will play a critical role in supporting Nexalin's efforts to deliver innovative, non-pharmacological solutions for Alzheimer's and related disorders.
Dr. David Owens serves as the Company's Chief Medical Officer and is a board-certified neuroradiologist and interventional neuroimaging specialist with more than 25 years of experience in brain and spine imaging. A graduate of Furman University and the Medical University of South Carolina, Dr. Owens completed residency and fellowship training at Emory University Hospital, where he specialized in interventional therapies for brain disorders before entering private practice. His expertise includes traumatic brain injury, neurocognitive disorders, and sports-related brain trauma.
Dr. Owens is a nationally recognized leader in advanced imaging techniques such as diffusion tensor imaging (DTI) and functional MRI. Over the past decade, he has also conducted and contributed to clinical research on transcranial stimulation therapies for conditions including anxiety, insomnia, clinical depression, and chronic pain—particularly in the context of reducing opioid dependency. Today, he operates a national teleradiology consultation practice focused on outpatient neuroimaging and continues to serve as a strategic clinical advisor in emerging neuromodulation technologies.
'This is a critical moment for innovation in Alzheimer's treatment,' said Dr. Scheer. 'Nexalin's technology represents a novel approach to brain modulation that could complement or even exceed the efficacy of traditional pharmacological therapies, particularly in the early stages of disease.'
The Company plans to initiate new Alzheimer's-focused clinical studies in the third quarter of 2025, incorporating cognitive testing, imaging biomarkers, and MEG-guided metrics to assess treatment efficacy and neural activation. The SAB will be instrumental in optimizing trial designs and ensuring adherence to regulatory standards and scientific rigor.
'I am excited to work alongside Nexalin's leadership and fellow SAB members to help guide the next generation of non-invasive neuromodulation therapies,' added Dr. Huang. 'The intersection of neuroimaging, brain stimulation, and clinical science holds enormous potential for treating neurodegenerative disease.'
This SAB reconstitution underscores Nexalin's continued evolution as a science-driven company committed to transforming mental health and neurodegenerative disease care through advanced bioelectronic medicine.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15-milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
Forward-looking statements
This press release contains statements that constitute 'forward-looking statements,' These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management 'believes', 'expects', 'anticipates', 'plans', 'intends' and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
13 minutes ago
- National Post
Review: Is the Nanit Pro baby monitor worth it?
Article content Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page. Article content When my husband and I first heard about the Nanit Pro baby monitor through a friend, I remember thinking, 'We don't need all that.' Article content Article content After all, we had already dropped thousands of dollars on a crib, bassinet, two Diaper Genies, what I had been assured was the Cadillac of strollers and a virtually indestructible car seat. Did we really need an infant monitor with so many bells and whistles? Article content Article content Fast forward 21 months, and it's one of the first things we suggest to new parents with a little one on the way. Below, I'll take you through what the Nanit Pro offers, how much it'll cost you, what I think some of its best features are, and how it might improve, before sharing my final recommendations. Article content With the Nanit, you can watch and listen in on your child, even when you navigate away from the app, thanks to the background audio and picture-in-picture feature. You can watch multiple kids via a split screen, and the Nanit can even alert you to changes in your child's breathing, if they're standing in the crib, or are somewhere they shouldn't be (like out of bed). Article content Article content It can also capture memories, celebrate milestones and deliver personalized, science-backed insights on your child's sleep and overall development. If your child cries in the middle of the night or tries to get out of the crib, you can play the video back to see exactly what happened and save it on your phone — depending on what subscription you get (but more on that later). Article content Article content The company has been around since 2014 and claims to have the 'largest database of infant sleep and development data' on the market, having clocked more than four billion hours of monitored sleep. The brand also boasts 54 patents and more than 30 developed AI components. Article content While the Nanit website offers everything from monitors, sound machines and breathing wear to apps and subscriptions, you can also opt to keep things simple (and more affordable) with just the camera and stand to monitor your baby via livestream.
CTV News
16 minutes ago
- CTV News
Timelapse of the auroras from Space
Watch Check out this timelapse video of the auroras from space that was captured by NASA astronaut Jonny Kim.
CTV News
an hour ago
- CTV News
Mike Johnson downplays Musk's influence and says Republicans will pass Trump's tax and budget bill
Speaker of the House Mike Johnson, R-La., wraps up a news conference on U.S. President Donald Trump's bill of tax breaks and spending cuts, at the Capitol in Washington, Wednesday, June 4, 2025. (AP Photo/J. Scott Applewhite) With an uncharacteristically feistiness, Speaker Mike Johnson took clear sides Sunday in U.S. President Donald Trump's breakup with mega-billionaire Elon Musk. The Republican House leader and staunch Trump ally said Musk's criticism of the GOP's massive tax and budget policy bill will not derail the measure, and he downplayed Musk's influence over the GOP-controlled Congress. 'I didn't go out to craft a piece of legislation to please the richest man in the world,' Johnson said on ABC's 'This Week.' 'What we're trying to do is help hardworking Americans who are trying to provide for their families and make ends meet,' Johnson insisted. Johnson said he has exchanged text messages with Musk since the former chief of Trump's Department of Government Efficiency came out against the GOP bill. Musk called it an 'abomination' that would add to U.S. debts and threaten economic stability. He urged voters to flood Capitol Hill with calls to vote against the measure, which is pending in the Senate after clearing the House. His criticism sparked an angry social media back-and-forth with Trump, who told reporters over the weekend that he has no desire to repair his relationship with Musk. The speaker was dismissive of Musk's threats to finance opponents — even Democrats — of Republican members who back Trump's bill. 'We've got almost no calls to the offices, any Republican member of Congress,' Johnson said. 'And I think that indicates that people are taking a wait and see attitude. Some who may be convinced by some of his arguments, but the rest understand: this is a very exciting piece of legislation.' Johnson argued that Musk still believes 'that our policies are better for human flourishing. They're better for the US economy. They're better for everything that he's involved in with his innovation and job creation and entrepreneurship.' The speaker and other Republicans, including Trump's White House budget chief, continued their push back Sunday against forecasts that their tax and budget plans will add to annual deficits and thus balloon a national debt already climbing toward $40 trillion. Johnson insisted that Musk has bad information, and the speaker disputed the forecasts of the nonpartisan Congressional Budget Office that scores budget legislation. The bill would extend the 2017 Trump tax cuts, cut spending and reduce some other levies but also leave some 10.9 million more people without health insurance and spike deficits by $2.4 trillion over the decade, according to the CBO's analysis. The speaker countered with arguments Republicans have made for decades: That lower taxes and spending cuts would spur economic growth that ensure deficits fall. Russell Vought, who leads the White House Office of Budget and Management, said on Fox News Sunday that CBO analysts base their models of 'artificial baselines.' Because the 2017 tax law set the lower rates to expire, CBO's cost estimates, Vought argued, presuming a return to the higher rates before that law went into effect. Vought acknowledged CBO's charge from Congress is to analyze legislation and current law as it is written. But he said the office could issue additional analyses, implying it would be friendlier to GOP goals. Asked whether the White House would ask for alternative estimates, Vought again put the burden on CBO, repeating that congressional rules allow the office to publish more analysis. Other Republicans, meanwhile, approached the Trump-Musk battle cautiously. 'As a former professional fighter, I learned a long time ago, don't get between two fighters,' said Oklahoma Sen. Markwayne Mullin on CNN's 'State of the Union.' He even compared the two billionaire businessmen to a married couple. 'President Trump is a friend of mine but I don't need to get, I can have friends that have disagreements,' Mullin said. 'My wife and I dearly love each other and every now and then, well actually quite often, sometimes she disagrees with me, but that doesn't mean that we can't stay focused on what's best for our family. Right now, there may be a disagreement but we're laser focused on what is best for the American people.' Bill Barrow, The Associated Press Associated Press journalist Gary Fields contributed from Washington.
